Laura Mitic, PhD

Chief Scientific Officer, Bluefield Project to Cure FTD
+1 415 514-8043

Laura Mitic, PhD, is the Chief Scientific Officer at the Bluefield Project to Cure Frontotemporal Dementia. Dr. Mitic holds a BA degree from Northwestern University and a doctorate degree in cell biology from Yale University. She completed postdoctoral studies at the University of California, San Francisco. She and her husband live in San Francisco with their two children.

Publications: 

CSF Proteomics in Patients With Progressive Supranuclear Palsy.

Neurology

Wise A, Li J, Yamakawa M, Loureiro J, Peterson B, Worringer K, Sivasankaran R, Palma JA, Mitic L, Heuer HW, Lario-Lago A, Staffaroni AM, Clark A, Taylor J, Ljubenkov PA, Vandevrede L, Grinberg LT, Spina S, Seeley WW, Miller BL, Boeve BF, Dickerson BC, Grossman M, Litvan I, Pantelyat A, Tartaglia MC, Zhang Z, Wills AA, Rexach J, Rojas JC, Boxer AL, as the 4-Repeat Tauopathy Neuroimaging Initiative

The Neurofilament Surveillance Project (NSP): A biomarker study to sample blood quarterly in familial frontotemporal lobar degeneration.

Alzheimer's & Dementia

Rachel Acuna-Narvaez, Hilary W. Heuer, Leah K. Forsberg, Anne Alward, Danielle Graham, Ann Fishman, Kevin M Nelson, Tyler Kolander, Howard M Fillit, Wendy R Galpern, Serena Hung, Chris Mason, Laurence Mignon, Yan G Ni, Arthur Simen, Ina Tesseur, Richard Tsai, Felix L Yeh, Carly T. Mester, Peter A. Ljubenkov, Howard J. Rosen, Bradley F. Boeve, Adam L. Boxer, Rodney Pearlman, Laura L Mitic, NSP Site Investigators

The role of neurofilament light in genetic frontotemporal lobar degeneration.

Brain Communications

Zetterberg H, Teunissen C, van Swieten J, Kuhle J, Boxer A, Rohrer JD, Mitic L, Nicholson AM, Pearlman R, McCaughey SM, Tatton N

Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration.

Neurology

Rojas JC, Wang P, Staffaroni AM, Heller C, Cobigo Y, Wolf A, Goh SM, Ljubenkov PA, Heuer HW, Fong JC, Taylor JB, Veras E, Song L, Jeromin A, Hanlon D, Yu L, Khinikar A, Sivasankaran R, Kieloch A, Valentin MA, Karydas AM, Mitic LL, Pearlman R, Kornak J, Kramer JH, Miller BL, Kantarci K, Knopman DS, Graff-Radford N, Petrucelli L, Rademakers R, Irwin DJ, Grossman M, Ramos EM, Coppola G, Mendez MF, Bordelon Y, Dickerson BC, Ghoshal N, Huey ED, Mackenzie IR, Appleby BS, Domoto-Reilly K, Hsiung GR, Toga AW, Weintraub S, Kaufer DI, Kerwin D, Litvan I, Onyike CU, Pantelyat A, Roberson ED, Tartaglia MC, Foroud T, Chen W, Czerkowicz J, Graham DL, van Swieten JC, Borroni B, Sanchez-Valle R, Moreno F, Laforce R, Graff C, Synofzik M, Galimberti D, Rowe JB, Masellis M, Finger E, Vandenberghe R, de Mendonça A, Tagliavini F, Santana I, Ducharme S, Butler CR, Gerhard A, Levin J, Danek A, Otto M, Sorbi S, Cash DM, Convery RS, Bocchetta M, Foiani M, Caroline V G, Peakman G, Russell L, Swift I, Todd E, Rohrer JD, Boeve BF, Rosen HJ, Boxer AL

Peripheral Innate Immune Activation Correlates With Disease Severity in GRN Haploinsufficiency.

Frontiers in neurology

Ljubenkov PA, Miller Z, Mumford P, Zhang J, Allen IE, Mitic L, Staffaroni A, Heuer H, Rojas JC, Cobigo Y, Karydas A, Pearlman R, Miller B, Kramer JH, McGrath MS, Rosen HJ, Boxer AL

Peripheral Innate Immune Activation Correlates with Disease Severity in GRN Mutation Carriers (P4.178).

Neurology

Peter Ljubenkov, Paige Mumford, Michael McGrath, Isabel Elaine Allen, Zachary Miller, Laura Mitic, Anna Karydas, Hilary Heuer, Julio Rojas-Martinez, Ping Wang, Jane Zhang, Adam Staffaroni, Yann Cobigo, Rodney Pearlman, Bruce Miller, Howie Rosen, Adam Boxer

An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations.

Alzheimer's & dementia (New York, N. Y.)

Sha SJ, Miller ZA, Min SW, Zhou Y, Brown J, Mitic LL, Karydas A, Koestler M, Tsai R, Corbetta-Rastelli C, Lin S, Hare E, Fields S, Fleischmann KE, Powers R, Fitch R, Martens LH, Shamloo M, Fagan AM, Farese RV, Pearlman R, Seeley W, Miller BL, Gan L, Boxer AL

Prosaposin is a regulator of progranulin levels and oligomerization.

Nature communications

Nicholson AM, Finch NA, Almeida M, Perkerson RB, van Blitterswijk M, Wojtas A, Cenik B, Rotondo S, Inskeep V, Almasy L, Dyer T, Peralta J, Jun G, Wood AR, Frayling TM, Fuchsberger C, Fowler S, Teslovich TM, Manning AK, Kumar S, Curran J, Lehman D, Abecasis G, Duggirala R, Pottier C, Zahir HA, Crook JE, Karydas A, Mitic L, Sun Y, Dickson DW, Bu G, Herz J, Yu G, Miller BL, Ferguson S, Petersen RC, Graff-Radford N, Blangero J, Rademakers R

MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes.

Alzheimer's & dementia (Amsterdam, Netherlands)

Bettcher BM, Fitch R, Wynn MJ, Lalli MA, Elofson J, Jastrzab L, Mitic L, Miller ZA, Rabinovici GD, Miller BL, Kao AW, Kosik KS, Kramer JH

Progranulin protein plasma and CSF levels in a large well-characterized dementia and healthy aging cohort. (S33.004).

Neurology

Zachary Miller, Laura Mitic, Jennifer Tran, Iryna Lobach, Anna Karydas, Ginette Serrero, Rodney Pearlman, Howard Rosen, Bruce Miller, Adam Boxer

Progranulin: at the interface of neurodegenerative and metabolic diseases.

Trends in endocrinology and metabolism: TEM

Nguyen AD, Nguyen TA, Martens LH, Mitic LL, Farese RV

The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).

Alzheimer's & dementia : the journal of the Alzheimer's Association

Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL

Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.

Alzheimer's & dementia : the journal of the Alzheimer's Association

Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J

SUMOylation of claudin-2.

Annals of the New York Academy of Sciences

Van Itallie CM, Mitic LL, Anderson JM

Claudin-2 forms homodimers and is a component of a high molecular weight protein complex.

The Journal of biological chemistry

Van Itallie CM, Mitic LL, Anderson JM

A role for autophagy in the extension of lifespan by dietary restriction in C. elegans.

PLoS genetics

Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M, Kenyon C

A Role for Autophagy Genes in the Extension of Lifespan by Dietary Restriction in C. elegans.

PLoS genetics

Malene Hansen, Abha Chandra, Laura L. Mitic, Brian Onken, Monica Driscoll, Cynthia Kenyon

Expression, solubilization, and biochemical characterization of the tight junction transmembrane protein claudin-4.

Protein science : a publication of the Protein Society

Mitic LL, Unger VM, Anderson JM

Occludin and Claudins.

Laura Mitic,Christina Van Itallie

Occludin localization at the tight junction requires the second extracellular loop.

The Journal of membrane biology

Medina R, Rahner C, Mitic LL, Anderson JM, Van Itallie CM

Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins.

American journal of physiology. Gastrointestinal and liver physiology

Mitic LL, Van Itallie CM, Anderson JM

Transmembrane proteins in the tight junction barrier.

Journal of the American Society of Nephrology : JASN

Fanning AS, Mitic LL, Anderson JM

Molecular architecture of tight junctions.

Annual review of physiology

Mitic LL, Anderson JM